These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31868025)

  • 1. The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma.
    Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
    Integr Cancer Ther; 2019; 18():1534735419888584. PubMed ID: 31868025
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
    Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
    Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study.
    Maschio M; Maialetti A; Marchesi F; Gumenyuk S; Pisani F; Papa E; Galiè E; Koudriavtseva T; Graziano G; Giannarelli D; Mengarelli A
    Integr Cancer Ther; 2022; 21():15347354221114142. PubMed ID: 35866451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
    Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.
    Ajewole VB; Cox JE; Swan JT; Chikermane SG; Lamoth B; Iso T; Okolo LO; Ford CL; Schneider AM; Hobaugh EC; Baker KR
    Support Care Cancer; 2020 Apr; 28(4):1901-1912. PubMed ID: 31359183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain.
    Zhi WI; Ingram E; Li SQ; Chen P; Piulson L; Bao T
    Integr Cancer Ther; 2018 Dec; 17(4):1079-1086. PubMed ID: 30027756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
    Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
    Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking TRPA1 and TNF-α Signal Improves Bortezomib-Induced Neuropathic Pain.
    Li C; Deng T; Shang Z; Wang D; Xiao Y
    Cell Physiol Biochem; 2018; 51(5):2098-2110. PubMed ID: 30522101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.
    Richardson PG; Schlossman RL; Roy AN; Panneerselvam A; Acharyya S; Sopala M; Lonial S
    Br J Haematol; 2018 Jun; 181(5):628-636. PubMed ID: 29774521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
    Sezer O; Beksac M; Hajek R; Sucak G; Cagirgan S; Linkesch W; Meltem Akay O; Gülbas Z; Nahi H; Plesner T; Snowden JA; Timurağaoğlu A; Dechow T; Lang A; Tuğlular T; Drach J; Armbrecht G; Potamianou A; Couturier C; Olie RA; Feys C; Allietta N; Terpos E
    Br J Haematol; 2017 Jul; 178(1):61-71. PubMed ID: 28382618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
    Werida RH; Elshafiey RA; Ghoneim A; Elzawawy S; Mostafa TM
    Support Care Cancer; 2022 Sep; 30(9):7281-7292. PubMed ID: 35596774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
    Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
    Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
    J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
    Vidisheva AP; Wang J; Spektor TM; Bitran JD; Lutzky J; Tabbara IA; Ye JZ; Ailawadhi S; Stampleman LV; Steis RG; Moezi MM; Swift RA; Maluso TM; Udd KA; Eshaghian S; Nassir Y; Berenson JR
    Support Care Cancer; 2017 Oct; 25(10):3217-3224. PubMed ID: 28455546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro.
    Takács A; Lajkó E; Láng O; Istenes I; Kőhidai L
    Sci Rep; 2020 Aug; 10(1):14287. PubMed ID: 32868799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study.
    Giraudet F; Selvy M; Kerckhove N; Pereira B; Barreau F; Nguyen D; Busserolles J; Cabrespine A; Chaleteix C; Soubrier M; Bay JO; Lemal R; Balayssac D
    Eur Arch Otorhinolaryngol; 2022 Apr; 279(4):2197-2201. PubMed ID: 35098333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and comfort of domestic bortezomib injection in real-life experience.
    Cerchione C; Nappi D; Pareto AE; Di Perna M; Zacheo I; Picardi M; Pane F; Catalano L
    Support Care Cancer; 2018 Sep; 26(9):3111-3116. PubMed ID: 29574618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.